CNS Pharmaceuticals, Inc.
CNSP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,197 | $1,167 | $3,243 | $1,498 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,056 | $1,241 | $1,094 | $1,701 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,253 | $2,408 | $4,337 | $3,199 |
| Operating Income | -$3,253 | -$2,409 | -$4,338 | -$3,200 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $35 | $34 | $36 | $24 |
| Pre-Tax Income | -$3,218 | -$2,375 | -$4,301 | -$3,176 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,218 | -$2,375 | -$4,301 | -$3,176 |
| % Margin | – | – | – | – |
| EPS | -104.35 | -77.04 | -18.96 | -2.96 |
| % Growth | -35.4% | -306.3% | -540.5% | – |
| EPS Diluted | -104.35 | -77.04 | -18.96 | -2.96 |
| Weighted Avg Shares Out | 31 | 31 | 226 | 1,841 |
| Weighted Avg Shares Out Dil | 31 | 31 | 226 | 1,841 |
| Supplemental Information | – | – | – | – |
| Interest Income | $37 | $39 | $43 | $26 |
| Interest Expense | $2 | $4 | $6 | $3 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$3,216 | -$2,370 | -$4,294 | -$3,173 |
| % Margin | – | – | – | – |